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A1. Study Title 
The relationship between chest X-ray findings, bacterial load and treatment-related 
outcomes in persons with extensively drug resistant tuberculosis. 
A2. Introduction, background and motivation 
Multi-drug resistant tuberculosis (MDR-TB) was first recognized in the 1990s with an 
increase in caseload of eighty-two percent between 2000 and 2007 (1). Extensively 
drug-resistant tuberculosis (XDR-TB), a more difficult and more expensive form of TB 
to treat with poorer outcomes (1), emerged in South Africa in 2006. The prevalence of 
XDR-TB is likely to be underestimated in South Africa as a result of incomplete 
detection and notification. In peri-urban areas like Khayelitsha where there are high 
rates of HIV, TB and poverty, the prevalence of MDR-TB is estimated at 51/100 000 
(2). A significant proportion of these cases are indeed undetected pre-XDR-TB (MDR 
and resistance to either a fluoroquinolone or a 2nd line injectable drug) and XDR (MDR 
and resistance to both fluoroquinolones and any one of the 2nd line injectable drugs) 
cases with inadequate access to drug sensitivity testing (2). Treatment outcomes of 
XDR-TB have been variable with countries like Peru showing a 60% overall cure (or 
completed treatment) rate, and studies in KwaZulu Natal in South Africa showing much 
poorer outcomes (3, 4). 
The reasons for the poor outcomes in XDR-TB remain unclear. We are continuing to 
investigate the role of strain-type and several other factors including nutritional status, 
degree of drug resistance, HIV status and drug regimens in determining outcomes. 
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There is a paucity of literature describing the chest X-ray (CXR) findings in patients 
with XDR-TB, and whether disease extent is related to treatment outcomes and the 
evolution of resistance remains unclear. It has been shown that patients with 
radiological extensive drug-sensitive TB have higher initial sputum mycobacterial loads 
and take a longer time to sputum conversion than those without (5, 6). The extent of 
disease on the CXR at baseline has been used as a tool to inform and predict the need 
for infection control measures, treatment duration, and outcomes (7, 8). 
The time-to-positivity (TTP) of mycobacterium tuberculosis in a liquid medium culture 
has become a validated indicator of bacterial sputum load (9, 10)  and indeed a surrogate 
bio-marker of treatment response to anti-tuberculosis drugs. The relationships between 
mycobacterial sputum load, radiological disease and treatment outcomes have been 
studied in drug-sensitive TB (5, 8), but little is known about XDR-TB. 
A3. Hypothesis 
More extensive disease, and cavitatory vs. non-cavitatory disease, are associated 
with higher bacterial load and unfavorable outcomes in patients with XDR-TB i.e. 
poorer rates of culture conversion and higher mortality.  
A4. Study Aim 
(i) To explore the relationship between the radiological features and treatment outcomes
(culture conversion, mortality, and treatment failure) in patients with XDR-TB. 
(ii) To explore the relationship between drug susceptibility profiles and radiological
features on CXR. 
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(iii) To study the relationship between measures of bacterial load (TTP and smear 
grade) and radiological features.  
A5. Outcome Measures 
(i) Cavitation and disease extent (cavitation vs. no cavitation; unilateral vs. bilateral; and 
total scores) 
(ii) Time to culture conversion and mortality, number of previous drug-resistant TB 
episodes, and the number of drugs the isolate is resistant to. 
(iii) Bacterial load (smear grade and TTP on MGIT culture) 
A6. Study Design 
This is a cross-sectional study with a follow-up component. 
Characteristics of the study population 
Patients admitted to BCH for XDR-TB treatment from October 2008 to October 2012. 
Inclusion criteria: All patients with a first-time diagnosis of XDR-TB who completed at 
least six months of treatment. Missing data will not be included but will be noted. 
Research procedures and data collection methods 
The data collection will occur at Brooklyn Chest TB hospital. Chest x-rays will be 
analyzed for cavitation and extent of disease using a scoring system (see Appendix 2). 
Patient folders will be examined for the relevant information on treatment-related 
outcomes (these have already been performed as part of the ongoing clinical registry). 
Smear status and TTP values at baseline will be recorded. The relationship between 
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disease extent and cavitation, and the evolution of resistance from pre-XDR to XDR-TB 
will be measured. 
 
A7. Data Analysis 
The frequency of the main radiological outcomes (e.g. number of zones, disease extent 
etc.) will be tabulated for each of the treatment-related outcome categories (e.g. 
mortality vs. no mortality). Other factors known to be associated with outcomes will 
also be tabulated (history of previous MDR-TB, total number of drugs the organism is 
resistant to, weight under 50kg, HIV status, CD4 count, and HAART usage). A 
multivariable analysis will be calculated for each outcome analysis (mortality and 
culture conversion). Data is to be extracted from folders and CXRs onto to a hard copy 
CRF and then an Excel spreadsheet.  
A8. Time Frame and Budget 
Submission of research proposal: May 2012 
Collection of data: June 2012 to April 2014 
Data analysis: April 2014 
Writing up and completion: May 2014 





A9. Ethical Considerations and Reporting of Results 
The study already has ethical approval as part of the ongoing prospective clinical 
registry. Results of the study will be submitted in fulfillment of a Masters of Medicine 
degree in Family Medicine at the University of Cape Town. The results of the study will 
be made available to all involved in the diagnosis and management of drug-resistant TB 
in Cape Town, and the National and Provincial Departments of Health. The findings of 
the study are expected to assist clinicians in providing better care for these and other 
patients. Once this study is completed, there is an intention to publish this study as a 
paper.  The PI declares no conflict of interests 
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B. Literature review 
B1. Introduction 
The purpose of this literature review is to critically assess the current level of 
knowledge of chest radiography in drug-resistant TB and in particular extensively drug-
resistant TB. To identify knowledge gaps in XDR-TB chest radiography and its 
relationship to sputum bacillary load and treatment-related outcomes (conversion; 
treatment failure and death).  
A Medline Pubmed search was conducted with filters including “core journal”; “last 10 
years”; “English”. Key search terms used included: “tuberculosis”; “chest radiography”; 
“cavitation”; “predictors”; “extensively drug-resistant “and “outcomes” 
B2. CXR Findings in Tuberculosis 
Chest radiography has been used in the diagnosis of TB for about a century. Today it 
remains an important tool alongside clinical and microbiological indicators in the 
management of TB. The chest X-ray (CXR) findings in drug-sensitive tuberculosis (DS- 
TB) are well documented. These may be categorised broadly into parenchymal disease 
(consolidation, cavitation, nodular and military patterns); pleural disease (thickening, 
calcification, effusion); and lymph node disease. Upper zone involvement with 
cavitation is the most common pattern seen in post primary disease in HIV uninfected 
patients. CXR findings in HIV infected patients are commonly bilateral, diffuse and 
involve the middle or lower zones (1). The CXR findings in drug resistant TB (with and 





There have been few studies comparing the CXR findings in DS-TB with those of drug-
resistant tuberculosis (DR-TB). Some studies have reported more extensive disease in 
DR-TB (2, 3). In an HIV uninfected cohort of 68 patients with DR TB (2), significantly 
more cavities but fewer large nodules were found in patients with primary multidrug-
resistant (MDR) or extensively drug-resistant (XDR) TB compared with 141 patients 
with primary DS-TB. There was no difference found between the CXRs in MDR and 
XDR-TB. In a retrospective review of 78 chest CT scans comparing primary MDR-TB 
with primary DS-TB Yeom JA (3) et al found bilateral involvement; consolidation and 
multiple cavities on CT scan more frequently in primary MDR-TB than DS-TB. 
Fishman JE (4) however, recorded similar radiographic findings for DS- and MDR-TB 
groups but more cavitation and consolidation in the acquired MDR group compared 
with the primary MDR group. Lessnau et al found no significant difference in chest 
radiography at presentation between DS and MDR-TB in 72 HIV infected patients 
residing in New York (5). In all these retrospective studies the time from infection to 
diagnosis (ie: the duration of active untreated disease) is a significant confounding 
variable. More rapid PCR-based diagnostics have reduced the time to diagnosis for 





Table 1. X-ray findings in patients with drug-resistant (DR) TB in comparison with DS-
TB   
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CXRs of patients with HIV tend to have more frequent lower lobe involvement, 
effusions and lymphadenopathy. There have been several studies which examine the 
differences in CXR findings in HIV infected and uninfected patients in the setting of 
DS- TB (6-9) but none in the context of DR-TB. In DS-TB it has been found that there 
is less consolidation and cavitation in HIV infected compared to uninfected patients and 
that patients with low CD4 counts are unlikely to have cavitation and may have normal 
chest x-rays (1, 10, 11).  
In contrast to this: of a cohort of 56 patients with MDR-TB (88% HIV positive) in 
Tugela Ferry Kwa-Zulu Natal South Africa, most were found to have severe pathology ( 
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a total of 39% with cavities and 62% with consolidation in 2 or more zones) on baseline 
CXR despite high rates of advanced immunodeficiency (12). The number of previous 
TB episodes, the time to diagnosis and time to treatment were not included here. Factors 
affecting host immunity such as nutrition and bacterial factors such as strain type are 
likely to play a role. These factors make it difficult to draw any conclusions between 
two different patient settings.  
B3. Scoring Systems for Chest Radiography in Tuberculosis 
Chest radiography is regularly used by clinicians to assist with diagnosis and 
monitoring of treatment in tuberculosis. Its usefulness, however, has been limited by 
poor specificity and high inter- and intra-observer variability. A simple standardised 
scoring system could assist in conjunction with other clinical parameters in case 
detection in an out-patient setting. It may be of value in predicting and monitoring 
response to treatment. In the setting of XDR-TB, where drug sensitivities are often not 
fully known and drugs generally less effective, a CXR scoring system may assist in 
tailoring individual regimens that are more likely to be successful. 
In a systematic review of scoring systems for the diagnosis of TB (13) it was found that 
all the included scoring systems combined radiological and clinical data rather than 
using radiological data alone. This limits the versatility of the system for use in other 
settings such as XDR-TB prognostic studies. The majority of scoring systems were 
designed as screening tools to assess the likelihood of a TB diagnosis to inform 
infection control measures in a hospital setting. Most studies revealed a high sensitivity 
and a low specificity and have been in well resourced, low burden countries. Most 




Anna P Ralph et al (14) developed and validated a simple numerical scoring system for 
use in smear positive adults with DS TB to assess severity of disease and  predict 
outcome. The outcome measure used was the 2 month smear status. The baseline CXR 
score was found to significantly predict the 2 month smear status and smear grade and 
the score was found to decrease over time with response to treatment. 
The CXR reading and recording system (CRRS) is a purely radiographic tool that was 
developed for use in epidemiological surveys for TB (15). It was developed and 
validated in a high TB burden setting in Cape Town South Africa. The overall intra and 
inter-reader agreement was found to be satisfactory and was confirmed among culture 
proven HIV co-infected cases (16). CRRS was designed as an epidemiological 
prevalence tool rather than a tool for diagnosing TB or monitoring treatment response in 
culture proven TB. Pinto et al (13) developed a numerical scoring system based on 
CRRS and suitable for use in the out-patient setting. It was found to have a high 
negative predictive value (a good rule out test) for smear negative and smear positive 
patients clinically suspected of having tuberculosis. Furthermore this system has 
advantages over other scoring systems in three areas: 
• Clinical data is not included in the score which allows it to be used by trained, 
non-clinical staff. This could make it more accessible as an adjunct to clinical 
tools and allows more versatility for use in a wider variety of settings including 
out-patient, hospital and research. 
• It has a weighted scoring system accounting the most prevalent X-ray findings in 
TB. 
• It appears to perform well in HIV infected patients (although this needs further 




Reliability of scoring systems 
None of the studies in a recent systematic review reported on the reliability of the 
scoring systems (17). In the all the studies which have reported on reliability the intra-
and inter-reader variability the range was from “fair” to ‘substantial” on variables such 
as consolidation or cavitation with most achieving a “moderate” score. Much lower 
levels of agreement were reached on variables such as “nodules” and 
“lymphadenopathy”.   
In many of the studies the CXR readers have been radiologists or experienced 
clinicians. The CRRS explores the idea that trained readers need not be clinicians. 
Notably in the CRRS study (15) an open training session of 50 CXRs in which some 
agreement was achieved preceded the study group analysis. Relatively higher levels of 
agreement were achieved with this system. 
B4. The CXR for Predicting Response to Treatment (smear or culture conversion) 
and Outcomes (cure, death and treatment failure) 
There are a number of studies which examine the relationship between X-ray findings at 
baseline and smear or culture conversion in DS-TB (14, 18, 19). It has been found that 
cavity and extent of disease on baseline CXR are associated with longer times to smear 
and culture conversion.(20) Most studies are in HIV uninfected patients or study 




There are few studies examining the baseline CXR of drug-resistant TB in relation to 
outcomes and fewer still in DR-TB populations with high HIV co-infection rates. In a 
study of 167 patients in Latvia with MDR-TB (21) bilateral cavitation, a history of 
previous MDR-TB and a high baseline bacterial load were found to be an independent 
predictors of a longer conversion time. The prevalence of HIV in this study was not 
commented on, however.  
Brust et al (12) reported no relationship between cavitation or consolidation and  
conversion time (after adjusting for smear status) in their study of 56 patients with 
MDR-TB ( 88% HIV co-infected). Here the only independent predictor of culture 
conversion was baseline smear status. The authors concluded, however, that smear 
status may have mediated the effect of cavitation on culture conversion. 
In a study in South Korea of 176 XDR-TB patients (22) (HIV uninfected) the previous 
use of second line drugs, linezolid, surgical resection and baseline cavitatory disease 
were found to be independent predictors of a poor outcome (death, failure and default) 
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Culture conversion in relation to outcomes 
Culture conversion and time to culture conversion is recognised as an early indicator for 
treatment outcome in tuberculosis. In a cohort of 167 patients with MDR-TB the 
median baseline sputum culture conversion time was 48 days among those who had a 
favourable outcome and 169 days among those with a poor outcome (P <0.001) (21). 
Delayed culture conversion has also been associated with an increased risk of relapse in 
some studies (20). In a recent prospective cohort of 107 patients with XDR-TB (23), 
time to conversion was found not to be associated with a favourable outcome. However, 
net culture conversion (in a series of conversions and reversions) was found to be 
independently predict survival. Time to culture conversion may be a less useful 
indicator of outcome in settings of high levels of drug-resistance and poor treatment 
response rates. 
There are limitations to conversion as an early surrogate indicator of outcome. In a 
systematic review Horne et al (24) found low sensitivity and only moderate specificity 
for smear and culture conversion as predictors of relapse or failure. The studies included 
here were predominantly of patients with DS-TB and the indicator used was the smear 
and culture status at 2 months. 
B5.  Chest Radiography and Sputum Bacterial Load 
The time-to-positivity (TTP) of mycobacterium tuberculosis in a liquid medium is a 
more sensitive indicator of bacterial load than smear status (25). It has become a 
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validated indicator of bacterial sputum load (26) and has been found to be a viable 
alternative to CFU (colony forming units) on solid media (27). Patients with more 
extensive disease and cavitation on CXR are known to have higher bacillary burdens 
and shorter TTPs (14, 28). In general, HIV infected patients have paucibacillary disease 
with longer TTPs and less disease and cavitation on CXR (10) 
Bacterial load in relation to outcomes 
In a study of 263 HIV uninfected, previously untreated, smear positive patients (20) 
culture conversion at 2 months was found to be associated with baseline extent of 
disease; cavities; smear grade and a baseline TTP>3 days. In multivariate analyses 
baseline TTP<=3 days and an extensive disease pattern on CXR were found to predict a 
delayed 2 month culture conversion, while a baseline TTP<=3 days also independently 
predicted relapse and recurrence of disease. 
In a small retrospective study, Epstein et al (25) looked at 26 consecutive patients with 
active TB and found serial TTPs to correlate well with treatment response and to be a 
valuable and more sensitive prognostic indicator than serial microscopy. In a study of 
167 patients in Latvia with MDR-TB (21) bilateral cavitation, a history of previous 
MDR-TB and a high baseline bacterial load (as measured by CFU count) were found to 
be an independent predictors of a longer conversion time.  
 
B6. Needs for Further Research 
Chest radiography remains a useful tool in the management of tuberculosis. There is, 
however, a need for further comparative descriptive studies in multidrug-resistant TB 
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with and without HIV co-infection. There is a knowledge gap in chest radiography in 
XDR-TB and XDR-TB HIV co-infection. The role of the CXR in predicting bacterial 
load (smear and TTP) and response to treatment in XDR-TB has not been described. 
The relevance of baseline and sequential TTP in predicting and monitoring response to 
treatment in MDR and XDR-TB needs to be clarified.  
There is a lack of standardisation of a simple, valid and reliable scoring system for 
CXRs in TB in high prevalent settings. A purely radiographic, numerical scoring system 
is relevant for future clinical research. The CRRS based numerical scoring system 
shows promise in this area and needs further validation studies in different settings. It 
may also prove to be very valuable in both the detection of cases and the management 
of DR-TB. 
Future prognostic studies in XDR-TB should quantify and consider the extent of disease 
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Background: The relationship between chest radiography, sputum bacillary load, and 
treatment outcome in patients with extensively drug-resistant tuberculosis (XDR-TB) 
has, hitherto, not been evaluated in TB and HIV endemic settings. 
Methods: Chest X-rays (CXRs) at diagnosis from 97 XDR-TB patients from South 
Africa were scored by 2 observers and findings correlated with sputum load at diagnosis 
(smear grade and culture time-to-positivity) and clinical outcomes (culture conversion 
and all-cause mortality).  
Results: 75/97(77%) had bilateral disease and 69/97(71%) had parenchymal 
involvement of ≥50% in extent. There was an association between the total radiographic 
disease score and risk of death [HR1.16 (1.05-1.28) p=0.003]. The total disease and 
cavitation score were inversely associated with culture conversion (p<0.0001 and p = 
0.0047, respectively) and time-to-conversion [HR0.85 (0.74-0.97) p=0.02].  The 
intraclass correlation coefficient for two CXR readers was 71.4% for the total score. 
Cavity and total scores were significantly lower in HIV-infected persons and did not 
correlate with outcome or bacterial load. 
Conclusions: Radiological disease extent and cavitatory scores correlated with 
outcomes and the latter correlated with bacterial load. Thus, quantitative radiographic 
scores may inform clinical decision-making and prognosis, and should be taken into 






Tuberculosis remains a global health problem. Drug-resistant strains of TB have poorer 
outcomes, are extremely costly to treat [1] and threaten the viability of already 
overburdened national TB programs. According to the WHO there has been a 42% 
increase in patients eligible for multi-drug resistant (MDR-TB) treatment since 2011 
[2]. In South Africa, more than 8000 cases of MDR-TB were identified in 2012 [2]. 
There is a growing epidemic of XDR-TB -  defined as MDR-TB with resistance to a 
fluoroquinolone and either capreomycin, amikacin, or kanamycin [3]. It is estimated 
that 9.6% of all MDR-TB patients have XDR-TB [2]. Outcomes for patients with XDR-
TB are extremely poor [4]. In a prospective cohort of 107 patients with XDR-TB 
Pietersen et al [5] reported a mortality of 78% and a favourable outcome of 11% at 60 
months from diagnosis. Thus, targeting more aggressive regimens at those with the 
worst prognosis is important. 
   
Chest X-rays (CXRs) have been used in the diagnosis of tuberculosis for about a 
century [6]. It is now used in screening, diagnosing and monitoring response to 
treatment. Despite being limited by poor specificity and high inter-observer variability it 
remains a useful adjunct to clinical and microbiological tools. Several CXR scoring 
systems have been developed to quantify disease and some have shown the potential to 





The extent of disease and cavities on baseline chest radiography are known to be 
associated with an increased sputum bacterial load [8-10], delayed smear and culture 
conversion [8, 11-13] and an increased risk of treatment failure [13, 14] in drug 
sensitive TB. Some authors have found cavities on the baseline chest radiograph in 
MDR-TB to be an independent predictor of bacterial load, longer conversion times [15] 
and poor outcomes [16] though relatively little has been reported in MDR-TB-HIV co-
infected patients [17-18]. 
There have been very few studies describing the chest radiograph in XDR-TB [19] or 
relating chest radiograph findings to outcomes [16] and none from TB endemic 
countries where the diagnosis is often delayed, and previous TB and other respiratory 
insults including HIV co-infection, exposure to mining dusts and biomass fuel exposure 
are common. Thus, radiographic findings and their prognostic value may differ 
considerably in such settings. Surprisingly, given the burden of XDR-TB in countries 
like South Africa there are no published studies evaluating the relationship between 
baseline chest radiography and bacterial load and outcomes.  
To address this issue we evaluated radiographic scores in a prospectively recruited 





In this prospective cohort study baseline chest radiographs of patients admitted to 
Brooklyn Chest TB Hospital (BCH) with XDR-TB between October 2008 and June 
2012 were evaluated. Brooklyn Chest Hospital is the primary TB referral hospital in the 
Western Cape and is situated in Cape Town. Most patients were managed as in-patients 
for the duration of the intensive (or injectable) phase of treatment and most remain in-
patients for longer than 6 months due to low conversion rates and poor treatment 
response [5, 20].  
XDR-TB treatment regimen and outcomes 
Patients received a standard regimen containing Capreomycin and PAS with a 
combination of some Group 5 drugs added at the discretion of the treating doctor [21]. 
Linezolid was not accessible. TB medication administered was directly observed by the 
ward staff. Side effects and co-morbidities were actively managed by doctors 
experienced in managing TB. Patients were seen regularly by adherence counsellors, 
social workers and occupational therapists while in hospital. Audiology screening for 
drug induced ototoxicity and chest radiography was done every two months. Treatment 
outcomes were assigned at censor date (31st October 2013) and regarded as favourable 
(cure or treatment completion) or unfavourable (default; treatment failure and death). 
Definitions were based on Laserson’s definitions of 2005 [22]. (Appendix 1)  
Ethics Statement 
Ethics approval was obtained as a sub-study from the human research ethics committees 




All included patients had isolates that were resistant to Rifampacin and Isoniazid. They 
were also resistant to Amikacin and Ofloxacin on phenotypic testing. A sub-group of 26 
of the 97 patients included in the study had extended drug sensitivity testing (DST) with 
a range of 4 to 13 drugs to which the isolate was resistant. 
Although the cohort was prospectively enrolled at Brooklyn Chest Hospital and basic 
radiographic information was captured at diagnosis (e.g. unilateral vs bilateral disease 
and presence or absence of cavitation) the detailed radiographic evaluation was only 
conducted towards the end of the parent study, which recruited 222 patients with XDR-
TB. However, at the time of detailed radiographic evaluation 109 patients had already 
been transferred out of the facility to peripheral clinics and other hospitals. Thus, only 
113 patient CXRs were available for detailed analysis. However, a sensitivity analysis 
did not show any significant differences between the study group of 97 patients and the 
total group of 222 patients in respect of age, gender, HIV status, and CD4 count. 
Chest radiographs dated closest to the date of diagnosis (sputum DST showing XDR-
TB) were chosen and those dated more than 3 months from the date of diagnosis were 
excluded (n=13). A further 3 CXRs were unreadable according to Chest Radiograph 




Chest radiograph analysis 
For the sake of external validity and generalisability the 97 chest radiographs were 
analysed independently by two non-specialist medical doctors. Prior to the study, both 
readers were trained by  two specialist pulmonologists experienced in TB diagnosis 
using  over 20 chest radiographs of patients with drug-resistant TB. The readers also 
attended a two day CRRS radiographic reading [23] course prior to the analysis. Criteria 
for cavities and disease extent were agreed before independently analysing the study 
radiographs. To delineate zonal borders two horizontal lines were measured at the lower 
border of the 2nd and 5th anterior costochondral junctions thus dividing the lungs into 6 
zones. Each of the 6 zones and was given a numerical score for the extent of disease 
(Disease Score) and for the number and size of the cavities (Cavity Score). Any 
parenchymal or pleural abnormalities were regarded as diseased and the area involved 
was estimated as more than or less than 50% of the total area. Cavities were declared 
where there was a clearly visible ring opacity of greater than 50% of the total 
circumference. Cavities less than 1 cm were not counted. Only the zone containing the 
majority of each cavity was selected. A “Total Score” was derived by the sum of the 
total disease and total cavitation scores for all 6 zones (Appendix 2). 
Statistical analysis 
Selected factors (history of previous multi-drug-resistant, total number of drugs the 
organism is resistant to, weight under 50kg, HIV status and CD4 count) known to be 
associated with outcomes (mortality and culture conversion) from previously published 
research were tested for association in this cohort using Wilcoxon-rank sum (for 
continuous variables) and Fisher’s exact test (for discrete variables). Anti-retroviral 
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therapy was not considered as all but 2 HIV-infected patients were on ARV treatment at 
the time of XDR-TB diagnosis. Univariate and multivariable logistic regression was 
applied, with variables carried forward to the multivariable case if p<0.1 in the 
univariate analysis. Culture conversion was assessed via a non-parametric competing 
risk model with death as the competing risk.  
C.5 Results
Patient demographic and clinical outcomes 
Of the 97 patients 63 (65%) were male. The median (IQR) body weight was 50 (46-59) 
kg. 53/97 (55%) had a previous history of drug-resistant TB. 44/97 (45%) were HIV 
infected with a median (IQR) CD4 of 132 (74.5- 301.5) cells/ml3 (Table 1.). The overall 
mortality rate was 64/97 (66%) for the whole cohort and 31/44 (71%) HIV infected and 
33/53 (62%) uninfected groups p=0.53 (Table 2). Treatment outcomes were poor: 86/97 
(89%) had an unfavourable outcome (Table 1). Of these, 7/86 (8%) defaulted, 40/86 
(47%) failed treatment and 39/86 (45%) died by censor date. Only 4 (4%) patients were 
cured.  
Chest radiograph findings 
Patients had extensive disease on chest radiograph at diagnosis. 75/97 (77%) had 
bilateral disease and 55/97 (57%) had cavitation (Table 2.). Patients with a history of 
previous drug-resistant-TB were more likely to have bilateral disease (p=0.026) but 
there was no significant difference in disease (p=0.68) or cavity scores (p=0.42). In the 
sub-group of 26 patients with extended DST we did not find an association between the 
number of drugs the isolate was resistant to and the baseline X-ray scores using 
Kendall’s tau test (p=0.78 (tau=-0.043) cavity and p=0.87 (tau=0.024) disease). 
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Disease extent and cavitation scores were lower for the HIV infected group: Median 
total score 7 (4-11) infected and 9 (6-12) uninfected (p=0.02) and median (IQR) cavity 
scores 0(0-0.9) infected and 1(0-2) uninfected (p<0.0001) (Table 2). 2 of the chest 
radiographs that were recorded as normal were both of HIV infected patients with CD4 
counts less than 200* 106/l.  
Chest radiographs related to conversion and mortality 
Patients who achieved culture conversion had lower total scores (disease plus cavitation 
scores): Median (IQR) total score 5 (4-7) conversion and 10 (6.38-12) no conversion 
(p<0.0001). The total score on chest radiograph was found to be inversely associated 
with conversion and time to conversion on multivariate analysis in the presence of death 
as a competing risk factor (HR=0.85 (0.74-0.97) p=0.02) (Table 4.) In the HIV sub-
group the cavity and total scores did not independently predict the likelihood of culture 
conversion. The total score was also found to independently predict the risk of death 
(HR=1.16 (1.05-1.28) p=0.003) (Table 5). 
Chest radiographs related to bacterial load 
Smear status was not significantly associated with disease (p=0.23) or cavity scores 
(p=0.76). Disease and cavity scores were however associated with time-to-positivity 
(TTP) (both p < 0.0001). There was a correlation found between disease score and TTP 
(p=0.071), and between cavity score and TTP (p=0.038), however chest radiograph 
scores were not found to predict TTP (Fig.2). 
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The Pearson intraclass coefficient (ICC) for reliability between two readers was 0.34 
(0.18 to 0.48) for cavity score - “moderate” correlation and 0.714 (0.62 to 0.79) for 




 Summary of main findings  
In this study total score (disease plus cavitation scores) strongly predicted the risk of 
death (HR=1.16 (1.05-1.28) p=0.003) (Table 5). Cavitation and the extent of disease on 
baseline chest radiography were found to be directly related to bacterial load at 
diagnosis.  Both cavity and total scores were significantly lower in the HIV-infected 
group and did not independently predict the likelihood of culture conversion or death in 
this sub-group. We have demonstrated the value of a valid and reliable scoring system 
in XDR-TB for both clinical and research purposes. Our study supports the current 
practice of using the chest radiograph as a tool for clinical management including 
selection of more aggressive regimens and to prognosticate in patients with XDR-TB. 
Interestingly, hardly any published data on XDR-TB takes into account radiographic 
scores when computing independent prognostic variables and biomarkers. These are 
important as there are few drugs to treat XDR-TB and the precise time of cure (culture 
negativity) if often difficult to establish. Thus, erroneous information may be obtained if 





Treatment outcomes for this group of patients have been poor with high rates of death 
and treatment failure [5]. 89% of our patients had died or failed treatment at the censor 
date. In view of the extremely poor mortality outcomes (thus impossible to sensibly 
compare groups) conversion and time to conversion were used as surrogate markers of 
treatment response. Conversion has been recognised as an early though imperfect 
indicator of treatment response [5, 15]. Indeed, we found initial culture conversion to 
independently predict the risk of death for both HIV infected and uninfected patients 
(Table 5.). 
Cavitatory disease on chest radiograph was first shown to be an independent predictor 
of time to culture conversion in 167 patients with MDR-TB [15] Our findings are 
similar with total disease score (disease plus cavitation scores) predicting culture 
conversion and time to culture conversion on multivariate analysis with death as a 
competing risk factor (Table 4). We have also found a previous history of drug-resistant 
TB [15] to independently predict the likelihood of culture conversion. In a study by 
Jeon et al [16] cavitation was shown to be an independent risk factor for poor outcomes 
in HIV un-infected patients with XDR-TB. Supporting this we found total score 
(disease plus cavity scores) to strongly predict the risk of death (Table 5.) in HIV 
uninfected but not HIV-infected persons (in the latter cavitation did not predict bacterial 
load). These observations in HIV infected persons is likely related to the low bacterial 
load in such patients, modulation of HIV on radiographic findings, and the substantial 
interaction between other factors such as CD4 count and mortality. 
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The TTP of Mycobacterium tuberculosis in a liquid medium is a more sensitive 
indicator of bacterial load than smear status [24]. Patients with more extensive disease 
and cavitation on chest radiograph are known to have higher bacillary burdens and 
shorter TTPs [8, 9]. In this study we have shown an inverse relationship between 
disease and cavity scores and TTP (Fig. 2). Patients who experienced culture conversion 
had significantly longer TTP’s at diagnosis [median (IQR) 18 (13-22) in converters 
versus 14 (10-21) non-converters p=0.03; Table. 1]. However, TTP did not 
independently predict culture conversion in the multivariate analysis. TTP is likely to be 
a less powerful indicator of treatment response in XDR-TB than in the drug sensitive 
[13] or MDR-TB group [15]. Reasons for this may include poor treatment response 
rates (thus higher bacterial load) and greater pre-existing lung damage in XDR TB 
(delay in the diagnosis).  
 
HIV-infected patients with drug sensitive TB are known to have less immunopathology 
and cavitation on the chest radiograph [25-27]. In this study of we have found lower 
chest radiograph scores in the HIV infected sub-group (Table 2). Despite advanced 
immune deficiency patients had advanced disease on chest radiograph at the time of 
diagnosis. This may reflect disease chronicity. In Tugela Ferry, KwaZulu Natal, Brust et 
al also found advanced radiological disease at diagnosis in MDR-TB (88% HIV-
infected) [17]. Factors that may account for this finding include more previous TB in 
patients with drug resistant-TB and delayed diagnosis. We found no association 
between baseline chest radiography and conversion or mortality in the HIV sub-group. 
This suggests that chest radiograph analysis in the context of HIV infected XDR-TB 
patients may have limited prognostic value. HIV co-infection may cause higher death 
rates related to disseminated TB and non-TB related causes, which may affect the 
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impact of the chest radiograph. These causes may be amplified by delayed diagnosis in 
paucibacillary TB. 
We highlight the importance of quantitative radiological analysis as a factor in 
predicting treatment response and prognosis in XDR-TB. In a recent systematic review 
it was found that most scoring systems combine clinical and radiological data to inform 
respiratory isolation in a hospital setting [28]. There is a need for a standardized 
radiological scoring system that is suitable for use in HIV infected and uninfected 
patients. We used a simple zonal scoring system that generates a numerical score and 
found it to be reliable for 2 readers. Since starting this study Pinto et al [7] developed a 
numerical scoring system based on CRRS [23] which was found to have a high negative 
predictive value (a good rule out test) for smear negative; smear positive and HIV-
infected patients clinically suspected of having tuberculosis. This has promise as a more 
comprehensive scoring system for use in clinical out-patient settings and in future 
research. 
The limitations identified in this study include the limited sample size as many patients 
had already been transferred out. Thus, the majority of patients who had been 
transferred out to clinics did not have accessible radiographs. It is possible therefore that 
the study group included a greater proportion of patients with more advanced disease. A 
sensitivity analysis did not however reveal any significant differences between the study 
group and the main cohort in respect of age; gender; HIV status or CD4 count. 
Furthermore, the sample size is still substantial for an XDR-TB-related study.  
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A small number of patients (n=26) had extended drug sensitivity available and the lack 
of association between the number of drugs to which the isolates were resistant and the 
baseline X-ray scores should be interpreted with caution. 
 
Conversion and time to conversion has limitations in predicting response to treatment 
and treatment-related outcomes [29]. We considered “initial” conversion in our study 
whereas “net conversion” (in a series of culture conversions and reversions) may be a 
more powerful indicator of treatment response [5].  
 
In conclusion we have shown that quantitative baseline chest radiography analysis in 
XDR-TB is independently associated with treatment response (culture conversion) and 
survival. We have also demonstrated a relationship between cavity and disease extent 
on chest radiograph and bacterial load (TTP). Thus, quantitative chest radiography 
remains relevant in the clinical management of HIV-uninfected patients with XDR-TB 
as it portends prognosis and informs the selection of more robust regimens when 
considering the cost-benefit and toxicity-harm analysis of an individualised regimen. 
Our findings also underscore the precept that radiological scores should be used to 
accurately compute the relative importance of prognostic biomarkers for XDR-TB. This 
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113 Patients with XDR-TB admitted to Brooklyn Chest 
Hospital and whose chest radiographs were accessible 
97 X-rays scored 
(at time of diagnosis) 
Excluded: 
• 13 X-rays more than 3
months from diagnosis
• 3 technically unreadable
53/97(55%) HIV uninfected patients 
• Weight>50kg: 25/53(49%)
• Previous DR-TB: 31/53(58%)
• Smear-positive: 24/53 (45%)
• Cavities on X-ray: 37/53 (70%)
• Bilateral disease: 49/53 (92%)
!
Conversion: 10/53 (19%) 
Outcomes: 
• Favourable: 1 (2%)
• Unfavourable: 46 (87%)
• Unclassified: 6 (11%)
Conversion: 15/44 (34%) 
Outcomes: 
• Favourable: 3 (7%)
• Unfavourable: 40 (91%)
• Unclassified: 1 (2%)
• Smear-positive: 18/44 (41%)
• Cavities on X-ray: 18/44 (41%)
• Bilateral disease: 26/44 (59%)
44/97(45%) HIV infected patients 
• Weight >50kg: 25/44 (57%)







Figure 2. Scatter plot of chest radiograph scores (cavity, disease, total) 
and time-to-positivity (days) in patients with XDR-TB. 
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Table 1. Clinical and radiographic characteristics of the cohort according to outcomes 
CLINICAL Total Alive  Deceased  P value Conversion  No Conversion P value 
n=97 n=33/97 (34%) n=64/97 (66%) n=25/97 (26%) n=72/97 (74%) 
Age years (median, IQR) 34 (27-42) 34 (27-37) 35 (27-45) 0.25 36 (29-41) 34 (25-43) 0.51 
Gender male 63/97 (65%) 23/33 (70%) 40/64 (62%) 0.63 17/25 (68%) 46/72 (64%) 0.9 
Weight kg (median, IQR) 50.3 (46-59) 53.2 (48-60) 50 (44-58) 0.05 55.25 (52-63) 49.7 (45-57) 0.01 
Diabetes 9/97 (9%) 4/33 (12%) 5/64 (8%) 0.75 3/25 (12%) 6/72 (8%) 0.89 
HIV-infected positive 44/97(45%) 13/33(39%) 31/64 (48%) 0.53 15/25 (60%) 29/72 (40%) 0.14 
CD4* 106/l (median, IQR) 123 (70-266) 122 (65-264) 123 (72-266) 0.91 119 (58-207) 124 (92-306) 0.34 
Previous DR-TB  53/97 (55%) 15/33 (45%) 38/64 (59%) 0.28 9/25 (36%) 44/72 (61%) 0.05 
Number of drugs 
resistant(median, IQR) 11 (8-12) 11 (9-12) 11 (8-12) 1 11.5 (11-12) 10 (8-12) 0.34 
Smear-positive 42/97 (43%) 10/33 (30%) 32/64 (50%) 0.03 5/25(20%) 37/72 (51%) 0.02 
Culture conversion 25/97 (26%) 20/33 (61%) 5/64 (8%) < 0.0001 
Time-to-positivity (TTP) 
days (median, IQR) 15 (11-22) 16 (13-22) 14 (10-21) 0.08 18 (13-22) 14 (10-21) 0.03 
Final treatment outcome 
(FTO) unfavourable 77/97(79%) 22/33(67%) 55/64(85%) 0.03 
Alive 20/25 (80%) 13/72 (18%) < 0.0001 
Died 5/25(20%) 59/72 (82%) < 0.0001 
X-RAY
Bilateral disease 75/97 (77%) 22/33 (67%) 53/64 (83%) 0.06 14/25 (56%) 61/72 (85%) < 0.0001 
Cavity Score(median, IQR) 0.5 (0-1) 0.5 (0-1) 0.5 (0-1.12) 0.76 0 (0-0.5) 1 (0-2) < 0.0001 
Disease Score(median, IQR) 7 (5-10) 5 (5-7) 9 (6-11) < 0.0001 5 (4-7) 9 (6-11) < 0.0001 
Total Score*(median, IQR) 8 (5.5-11.75) 6 (5-8.5) 10 (6-12) < 0.0001 5 (4-7) 10 (6.38-12) < 0.0001 
# # # # # # # # #Data are number(%)unless otherwise indicated. *Total score = disease score plus cavitation score 
48#
#
Table 2. Clinical and radiological characteristics of the cohort according to HIV 
status  
CLINICAL Total HIV infected HIV non-infected P value 
n=97 n=44/97(45%) n=53(55%) 
 
    Age years (median, IQR) 34 (27- 42) 36 (32- 41) 33 (24-45) 0.17 
Gender male 63/97 (65%) 24/44 (55%) 39/53 (74%) 0.08 
Weight kg (median, IQR) 50 (46-59) 54 (46-63) 50 (46-55) 0.22 
Diabetes 9/97(9%) 6/44 (14%) 3/53(6%) 0.32 
CD4* 106/l (median, IQR) 
    Previous DR-TB  53/97 (55%) 22/44 (50%) 31/53 (59%) 0.53 
Number of drugs 
    resistant(median, IQR) 11(8-12) 11.5 (11-12) 9.5 (8-12) 0.15 
Smear-positive 42/97 (43%) 18/44 (41%) 24/53 (45%) 0.78 
Culture conversion 25/97 (26%) 15/44 (34%) 10/53 (19%) 0.14 
Time-to-positivity (TTP) 
    days (median, IQR) 15 (11-22) 15 (11-23) 15 (11-20) 0.54 
Final treatment outcome 
    (FTO) unfavourable 86/97 (89%) 40/44 (91%) 46/53 (87%) 0.12 
Alive 33/97(34%) 13/44 (30%) 20/53 (38%) 0.53 
Died 64/97 (66%) 31/44 (71%) 33/53(62%) 0.53 
 
X-RAY
    Bilateral disease 75/97 (77%) 26/44 (59%) 49/53 (93%) < 0.0001 
Cavity Score (median, IQR) 0.5 (0-1) 0 (0-0.9) 1 (0-2) < 0.0001 
Disease Score(median, IQR) 7 (5-10) 6 (4-10) 8 (6-10) 0.08 
Total Score*(median, IQR) 8 (6- 12) 7 (4-11) 9 (6-12) 0.02 
Data are median (IQR) or n (%), unless otherwise stated. *Total score = disease 
score plus cavitation score 
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Table 3. Univariate Cox proportional hazards regression model of clinical and 
radiographic factors associated with risk of death for all patients given 
treatment for XDR-TB and in HIV-infected patients only. 
*Total score = disease score plus cavitation score
FULL COHORT HIV COHORT 
    HR**(95%CI) pvalue HR**(95%CI) pvalue 
     Age (years) 1.01 (0.99-1.04) 0.24 0.98 (0.93-1.02) 0.3 
Gender male 0.93 (0.56- 1.55) 0.79 1.45 (0.70-3.01) 0.31 
Weight (kg) 0.97 (0.95- 0.997) 0.03 0.99 (0.95- 1.02) 0.34 
Diabetes  0.67 (0.27- 1.68) 0.39 0.29 (0.07- 1.24) 0.1 
HIV-infected positive 1.38 (0.84- 2.27) 0.2 
  CD4 ( *106/L) 0.999 (0.997-1.00) 0.63 0.999 (0.997- 1.00) 0.63 
Previous DR-TB 1.35 (0.82- 2.23) 0.24 3.13 (1.43- 6.83) 0.004 
Previous MDR-TB 1.05 (0.63- 1.73) 0.9 2.43 (1.14- 5.20) 0.02 
Previous Pre XDR-TB 1.15 (0.66- 2.00) 0.63 1.87 (0.86- 4.05) 0.11 
Number of drugs resistant 1.00 (0.81- 1.25) 0.99 0.96 (0.61- 1.52) 0.86 
Smear positive 1.96 (1.11- 3.46) 0.02 2.28 (0.96- 5.43) 0.062 
Smear no data 1.71 (0.84- 3.47) 0.14 1.77 (0.66- 4.74) 0.259 
Culture conversion 0.11 (0.05- 0.28) < 0.0001 0.10 (0.03- 0.32) < 0.0001 
TTP(days) 0.96 (0.92- 1.00) 0.07 0.97 (0.92- 1.03) 0.35 
FTO Unfavourable 1.3 (0.40-4.21) 0.66 1.15 (0.15- 8.60) 0.89 
FTO Unclassified 0.49 (0.12- 1.98) 0.32 0.79 (0.09- 6.84) 0.83 
Diagnosis to treatment (days) 0.998 (0.997- 1.00) 0.05 0.999 (0.996- 1.00) 0.24 
Diagnosis to x-ray(days) 0.996 (0.988- 1.00) 0.27 0.99 (0.98- 1.00) 0.09 
 X-RAY
    Unilateral disease 0.52 (0.26- 1.05) 0.07 0.5 (0.22- 1.14) 0.1 
Clear x-ray 6.61 (1.52-28.79) 0.01 4.32 (0.93- 19.99) 0.06 
Cavity score 1.26 (0.99- 1.6) 0.06 1.48 (0.94- 2.35) 0.09 
Disease score 1.24 (1.13- 1.36) < 0.0001 1.21 (1.07- 1.37) 0.002 
Total score* 1.18 (1.10- 1.28) < 0.0001 1.18 (1.07- 1.31) 0.001 
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Table 4. Multivariate Cox proportional hazards model of clinical and 
radiographic factors associated with culture conversion in the presence of the 





HR**(95%CI) P value 
Age (years) 0.99(0.95-1.04) 0.79 
Weight (kg) 1.03(0.99-1.07) 0.15 
Diabetes 0.65(0.14-2.98) 0.58 
HIV-infected  1.33(0.50-3.50) 0.57 
Previous DR-TB 0.36(0.15-0.91) 0.03 
X-RAY
  Total Score* 0.85(0.74-0.97) 0.02 
*Total score = disease score plus cavitation score
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Table 5. Multivariate Cox proportional hazards model of clinical and 
radiographic factors associated with risk of death for all patients given 
treatment for extensively drug-resistant tuberculosis, and in HIV-infected 





    
 
HR**(95%CI) P value HR**(95%CI) P value 
Weight (kg) 0.98(0.95-1.01) 0.13 – – 
Diabetes – – 0.23(0.05-1.02) 0.05 
Previous MDR-TB – – 1.89(0.80-4.45) 0.15 
Culture conversion 0.11(0.03-0.37) 
< 
0.0001 0.21(0.05-0.93) 0.04 
TTP(days) 0.99(0.95-1.04) 0.79 – – 
Diagnosis to treatment(days) 1.00(1.00-1.00) 0.67 0.99(0.98-1.01) 0.31 
X-RAY
    Unilateral disease 2.05(0.82-5.14) 0.13 1.26(0.34-4.67) 0.73 
Disease score – – 1.19(0.95-1.48) 0.13 
Total score* 1.16(1.05-1.28) 0.003 – – 














D2. Technical appendices 
D2.1 Laserson’s definitions (38) 
Cure 
An MDR-TB patient who has completed treatment according to country protocol and has been 
consistently culture-negative (with at least five results) for the final 12 months of treatment. If only 
one positive culture† is reported during that time, and there is no concomitant clinical evidence of 
deterioration, a patient may still be considered cured, provided that this positive culture is followed by 
a minimum of three consecutive negative cultures, taken at least 30 days apart. 
Treatment completed 
An MDR-TB patient who has completed treatment according to country protocol but does not meet 
the definition for cure or treatment failure due to lack of bacteriologic results (i.e., fewer than five 
cultures were performed in the final 12 months of therapy). 
Death 
An MDR-TB patient who dies for any reason during the course of MDR-TB treatment. 
Treatment default 
An MDR-TB patient whose MDR-TB treatment was interrupted for 2 or more consecutive months for 
any reason. 
Treatment failure* 
Treatment will be considered to have failed if two or more of the five cultures recorded in the final 12 
months are positive, or if any one of the final three cultures is positive. Treatment will also be 
considered to have failed if a clinical decision has been made to terminate treatment early due to poor 
response or adverse events. 
Transfer out 
An MDR-TB patient who has been transferred to another reporting and recording unit and for whom 
the treatment outcome is unknown. 
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D2.2 Appendix 2 
CXR scoring sheet for drug- 




<50% of area affected 
≥ 50% of area affected 
Cavitation (b) 
No cavitation 
Single cavity,  <2cm diameter 
Single cavity, 2- 4cm diameter 
Single cavity, >4cm diameter 
Multiple cavities, largest <2cm diameter 
Multiple cavities, largest 2-4cm diameter 
Multiple cavities, largest >4cm diameter  
    Symbol     Score 
  Leave blank 
<
>
 Leave blank 
    1a 
    1b 
    1c 
    2a 
           2b 




       0 
      0.25 
      0.50 
      1.00 
      0.50 
      1.00 
      2.00 
  Bilateral 
  Effusion 
  Glands 
  Unilateral 
Zone definition 
DATE 





Total score(a) + (b) 
↓ 
Composite score all zones . 
DATE: 





Total score(a) + (b) 
↓ 
Composite score all zones . 
DATE: 





Total score(a) + (b) 
↓ 








D3. European Respiratory Society research journals manuscript submission 
guidelines  
Before submitting a manuscript to the ERS research journals (the European Respiratory Journal and ERJ Open 
Research), please read these guidelines carefully. Adherence to the guidelines will help to ensure smooth and 
prompt peer review. The other ERS journals (European Respiratory Review and Breathe) have their own specific 
manuscript preparation guidelines.  
All submissions to the ERS research journals are handled via the ScholarOne Manuscripts platform, which 
provides detailed instructions about the submission process. If you experience problems or require any further 
assistance, please contact the submission helpline direct on +44 114 2672864 or contact Gill Archer, ScholarOne 
Manuscripts coordinator.  
• Overlapping publications and publication ethics
• Manuscript preparation
• Original articles
• Review and series articles
• Letters and correspondence
• Online supplementary material and video summaries
• Guidelines for reporting research findings
• Data availability and publication
• Registering clinical trials
• Permission to re-publish materials
• Authorship
• Conflict of interest
• Proofs
• Correction policy
• Appendix: sources of statistical information
Overlapping publications and publication ethics top 
Authors submitting a paper to the ERS research journals do so on the understanding that neither the work nor any 
part of its essential substance, tables or figures have been or will be published or submitted to another scientific 
journal or are being considered for publication elsewhere. This must be stated in the cover letter. This restriction 
does not apply to conference abstracts or material published under legal requirements for clinical trials reporting, 
but includes work published in another language.  
It is the authors' responsibility to ensure that submitted manuscripts are not duplicate publications; they must 
declare any simultaneous submissions of similar or related manuscripts at the point of submission and must 
include electronic copies of these manuscripts as a supplement to their submission. If there are any concerns 
following submission, the editors reserve the right to take appropriate action.  
The ERS uses iThenticate plagiarism detection software (www.ithenticate.com). Submitted articles are screened 
and compared to previously published sources. Manuscripts revealing a high proportion of similarity to single or 
multiple published sources will be examined carefully, and the Chief Editors reserve the right to approach 
authors for an explanation (as per the Committee on Publication Ethics recommendations of procedures to follow 
in the event of suspected plagiarism in a submitted manuscript).  
As a member of the Committee on Publication Ethics, the ERS follows the COPE codes of conduct and best 
practice guidelines.  
Manuscript preparation top 
Presentation of manuscripts should be consistent with the Recommendations for the Conduct, Reporting, Editing, 
and Publication of Scholarly Work in Medical Journals, as recommended by the International Committee of 
Medical Journal Editors (ICMJE). 
Brief requirements for journal articles are summarised in the following table. The requirements are outlined in 
more detail below.  
Article type Word limit Figures and tables*  References Online supplement Abstract 
Original research 3000  8  40  Accepted Yes, 200 words
Editorials 1500  2  30  Not accepted No 
Review and series 
articles 5000  5  200  Accepted Yes, 200 words
Research letters 1200  1  15  Not accepted No 
Correspondence 800  1  10  Not accepted No 
Task force reports, 
guidelines and 
consensus statements 
8000  15  250  Accepted Yes, 200 words
*The number of figures and tables in the above summary refers to the combined number; for example, letters can
have either one figure or one table, not one of each.
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For further general guidance on how to write papers, please refer to: Sterk PJ, Rabe KF. The joy of writing a 
paper. Breathe 2008; 4: 224-232, and guidelines for authors on how to write scientific articles to be published in 
English at http://www.ease.org.uk/pdfguidelines/AuthorGuidelinesHighRes.pdf 
Authors are reminded that they should not imply that any opinions or views expressed in their article are those of 
the journal. 
General 
• Write the manuscript in UK English.
• The manuscript file you submit must be saved in rich text format (.rtf) or as a Microsoft Word
document (.doc or .docx).
• Describe abbreviations and unusual terms at the first time of use.
• Symbols as defined by the ad hoc working group of the Commission of the European Communities
(see Eur Respir J 1993; 6: Suppl. 16) are recommended.
• Système International (SI) units are recommended.
• Equations should be created as normal text.
Title page 
• Provide a concise and informative title, limited to 90 characters (including spaces).
• Include a list of all contributing authors and all of their affiliations, with a clear indication of who is
associated with each institution.
• Supply the full correspondence details for the corresponding author, including e-mail address. Only one
corresponding author per manuscript should be provided.
• Provide a 120-character (including spaces) summary of the "take home" message of your paper, which
can be used to publicise your study via social media.
Tables 
• Insert tables into the main text document using the Table function in your word processing package. Do
not supply tables in a separate file.
• Number tables consecutively with Arabic numerals.
• Limit data to a sensible number of significant figures.
• Avoid large tables if possible. Large tables are difficult to display on small screens or A4 printouts.
• Provide a clear footnote for each table, making sure all abbreviations and symbols used are defined.
• For reference numbering schemes, citations made in tables should continue in numerical order from the
point in the main body text where the table is first cited.
Figures 
File format 
• Supply line-art figures in JPEG, TIFF, Adobe Illustrator (.ai), PDF, SVG or EPS format. Graphs or bar
charts may be supplied in Excel or similar spreadsheet format.
• Supply halftone and photographic images in PSD, JPEG or TIFF format. Minimum resolution should
be 300 dpi at the final printable size (90 mm wide or greater).
• Don’t embed images in the main manuscript file. Supply them separately.
• If your figures were originally created in another format that contains extra information (e.g. embedded
data in an Excel graph), consider supplying them as supplementary material (Original Articles only).
Size and quantity 
• Figures constitute a key element of manuscripts submitted to the ERS research journals. However,
figures should be limited (both in size and number) to those required to show the essential features
described in the manuscript.
• Avoid large figures comprising many individual parts: as a maximum, each individual figure must fit to
a single PDF page of the journal, with sufficient space for its accompanying caption.
• If you have a large number of figures, consider publishing some of them as an online supplement.
• Images should be submitted in as close a size as possible to the final print size. There are three options:
90, 140 or 190 mm.
Colour figures 
• There is a charge for presenting figures in colour in the printed edition of the European Respiratory
Journal; figures can be presented in colour online free of charge in both the European Respiratory
Journal and ERJ Open Research.
• There is no charge for presenting figures in colour in ERJ Open Research.
• Please remember that people are likely to print your manuscript on a black-and-white printer. Your
colour figures need to be comprehensible when printed in this format.
Figure presentation 
• All submitted figures must be clearly named and numbered.
• Whether for images, drawings or graphs, use no more than four panels for a single figure. These should
be labelled as a), b), c) and d).




• Radiographic images should be of high quality and combined into one array, such as posteroanterior
and lateral views. Each panel should be sized identically.
• When several photographic or halftone images of a given type are being shown, please reproduce them
all at the same magnification.
• Photomicrographs must have internal linear scale markers (scale bars), since the size and magnification
may be altered when the figure is printed or displayed on screen.
• Images should correspond in appearance to the tonal relations of the original radiograph (i.e. showing
the bones white on a dark background), with the patient's right to the observer's left. CT scans and
magnetic resonance images should employ the internationally accepted 'view from below'.
• Label your images such that all important details are clearly marked, but avoid obscuring large areas of
the images with excessive labelling.
• Use a sans serif font (such as Arial or Helvetica) for labelling, and ensure that the font is legible, of
reasonable size and uniform throughout all the figures in your manuscript.
• Ensure that bar charts and graphs have a white background, with no shading or gridlines.
• Use greyscale shading on bar charts and graphs (different weights can be used, e.g. from 0% (white) to
100% (black) for purposes of differentiation), in preference to hatching and patterning.
• Do not use three-dimensional effects in the presentation of bar charts.
• For reference numbering schemes, citations made in figures should continue in numerical order from
the point in the main body text where the figure is cited.
Guidelines for handling image data 
• If an image has been enhanced electronically, please explain the alterations that have been made and
submit the original image along with the enhanced one. Keep an electronic set of original images, since
our reviewers might ask you to modify their content and the display modus.
• The Council of Science Editors has established four basic guidelines for handling image data, which
authors submitting to the ERS research journals are urged to comply with. 1) No specific feature within
an image may be enhanced, obscured, removed or introduced. 2) Adjustments of brightness, contrast or
colour balance are acceptable if they are applied to the whole image and as long as they do not obscure,
eliminate or misrepresent any information present in the original. 3) The grouping of images from
different parts of the same gel, or from different gels, fields or exposures must be made explicit by the
arrangement of the figure (e.g. by using dividing lines) and in the text of the figure legend. 4) If the
original data cannot be produced by an author when asked to provide it, the acceptance of the
manuscript may be revoked.
Captions 
• Provide a clear caption for each figure.
• Captions should be brief and not repetitive of information given in the text.
• All abbreviations should be expanded.
• Where appropriate, captions should include the imaging technique used, the body part imaged and any
noteworthy details.
• Mention any use of internal scale bars.
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• Number references consecutively in the order in which they first appear in the text, using full-sized
Arabic numerals in square brackets to cite references.
• All authors must be included for each cited item.
• References should contain at all the information shown in the following examples:
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• Documents published online, and individual web pages, should be listed in the reference list, not in the
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information shown in this example (include the author of the webpage, its title, the URL on which the
cited material can be found, and the dates on which the webpage was last accessed by you, and on
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• References to websites as a whole or sections of websites (rather than particular pages or documents on
a website) should be included directly in the text:
...data was sourced from the WHO Global Health Observatory 
(http://www.who.int/gho/en/)... 
• Works that have not yet been accepted for publication and personal communications should not appear
in the reference list. These should be mentioned directly in the text.
• A copy of any paper cited as "in press" and not yet available online should be uploaded to the
submission platform as supporting material.
Original articles top 
Original articles should not exceed 3000 words (you do not need to include the abstract, references, tables and 
figure captions in this word count). If your manuscript exceeds this limit, please state the final word count and 
explicit reasons for exceeding the limit in your covering letter.  
The total number of figures and/or tables should be limited to no more than eight. Large figures with more than 
four parts should be avoided: these can be presented as online supplementary material. More information 
regarding figures can be found above.  
Abstract 
Please provide an abstract of 200 words or fewer, which is easily understood without reference to the text (see 
Ann Intern Med 1987; 106: 598-604).  
The abstract should have four separate paragraphs, which correspond to: the question addressed by the study; 
materials/patients and methods; results; and the answer to the question. One or two sentences of background 
information can be included in the opening paragraph if necessary. The question and answer should be the same 
as those in the text.  
Include only the most important numbers and results, and avoid using abbreviations. 
Introduction 
In the introduction, state the question you asked (or hypothesis to be tested) and your considerations leading to 
the formulation of the question. Give only pertinent references.  
Material and methods 
Study subjects or animals 
• Clearly describe how the subjects or experimental animals were identified, including the control
subjects when used. For animals, see Laboratory Animals 1985; 19: 106-108.
• Clearly state the eligibility criteria for cases and controls in observational studies, or for subjects in
clinical trials.
• All work involving studies on human subjects must have received approval from local ethics
committees and the regulatory authority (when appropriate: for example, for drug trials). Written
informed consent must also have been obtained from all subjects and this must be clearly indicated in
the paper. See also guidance on the reporting of clinical trials, below.
• Animal experimentation must have been performed according to the Helsinki convention for the use
and care of animals.
• Provide details of the species and/or strain and number of animals involved in the study.
• The editors will reject work that does not conform to acceptable ethical criteria.
Study design 
• Clearly state the main study objective(s).
• Consider sample size and whether you have enough subjects to reliably address the research question.
• Manuscripts reporting clinical trials should include details of the sample size calculation (i.e. the
expected effect size, power, level of statistical significance and one- or two-sided test).
• For systematic reviews, make sure that the keywords used to search electronic medical databases cover
different terminology (for example, tumour or cancer) and spelling (for example, randomised or
randomized).
Methods 
• Provide an overview of the main tests or experiments.
• Describe the methods and apparatus in sufficient detail to allow other workers to evaluate or reproduce
the tests/experiments.
• For methods that have been published before, provide a reference only, or a reference and brief
description.
• Identify drugs and chemicals, including generic name, dosage and route of administration.
• Provide manufacturers’ names and addresses (city and country) for equipment, drugs, chemicals and
software as necessary, but not in a separate section.
Analysis 
• Clearly state and define the main outcome measure(s).
• Briefly state the statistical methods used during the analysis if they are standard. Describe any new
methods and justify their use.
• In the case of single- or multicentre trials with blinded intervention, the code must have been broken at
the end of the study in the presence of the responsible investigator of each centre. The code and the
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data will then be available to each participating centre. The first author should make provisions so that 
if needed, the data are available to the editors for independent statistical analysis.  
• Seek advice from a statistician on the appropriate methods of analysis and whether results have been
interpreted correctly.
Results 
• Keep the results section brief.
• Describe the baseline characteristics or condition of patients or animals.
• Focus on the important results, i.e. those that help to address the research question.
• Present most data in figures or tables, not in the text. Use the text to emphasise or summarise the most
important observations.
Discussion 
• At the beginning of the discussion, summarise the main results, and show how they have addressed the
research question.
• Make sure that the conclusions are consistent with the results and are pertinent to the research question.
• Describe the limitations of the study and/or analysis, and discuss their possible implications for the
conclusions.
• Emphasise the new and important aspects of the study.
• Try to explain contradictory or unexpected results, or discrepancies with previous findings.
•
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